<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: This study examines whether malignant disease under treatment influences the incidence of <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> or FK-506 neurotoxicity after myeloablative conditioning and allogeneic bone marrow transplantation (allo-BMT) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Review of 290 patients who received myeloablative conditioning prior to allo-BMT and <z:chebi fb="0" ids="4031">cyclosporine</z:chebi>/FK-506 identified 21 (7.2%) patients with neurotoxicity confirmed by computed tomography or magnetic resonance </plain></SENT>
<SENT sid="2" pm="."><plain>Underlying <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> necessitating allo-BMT included <z:hpo ids='HP_0001909'>leukemias</z:hpo> (67%), <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (10%), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (10%), and <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (MM) </plain></SENT>
<SENT sid="3" pm="."><plain>Frequency of neurotoxicity by disease was compared </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The highest incidence of neurotoxicity was present with MM (25%), whereas the lowest incidence was present with <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (2.7%) </plain></SENT>
<SENT sid="5" pm="."><plain>Other diseases demonstrated intermediate incidence, including <z:hpo ids='HP_0002488'>acute leukemias</z:hpo> (10%), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (6.4%), and <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (4.9%) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: <z:chebi fb="0" ids="4031">Cyclosporine</z:chebi>/FK-506 neurotoxicity varied according to the underlying <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The variable susceptibility to the development of neurotoxicity in this population may depend on the interaction of host vasculature with disease specific factors </plain></SENT>
<SENT sid="8" pm="."><plain>Understanding the cause of neurotoxicity could improve survival after allo-BMT </plain></SENT>
</text></document>